Glycyrrhetinic acid-modified TPGS polymeric micelles for hepatocellular carcinoma-targeted therapy
作者： Xiumei Zhu , Altansukh Tsend-Ayush , Zhongyue Yuan , Jing Wen , Jiaxin Cai
DOI: 10.1016/J.IJPHARM.2017.07.011
关键词:
摘要: In this study, glycyrrhetinic acid (GA)-modified D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) polymeric micelles (TGA PMs) were developed for the delivery of etoposide (ETO) to hepatoma cells. GA was incorporated as a ligand because its high affinity hepatocytes, while TPGS functioned P-gp inhibitor reverse multidrug resistance. ETO-loaded TGA PMs (ETO-TGA displayed mean particle size 133.6±1.2nm with low poly-dispersity index (0.224±0.013) and negative zeta potential (-16.30mV). The drug loading entrapment efficiency ETO-TGA 10.4% 79.8%, respectively. also exhibited faster release behavior at pH 5.8 relatively stable 7.4. Confocal laser scanning microscope (CLSM) observations in vivo imaging studies revealed that higher cellular uptake selective accumulation tumor site, indicating good targetability. Furthermore, significant cytotoxicity towards HepG2 cells anti-tumor efficacy (75.96%), compared control group. This could be due TGA-mediated targeted hepatocytes well inhibition. These findings suggest have used system hepatic cancer therapy.
sci-hub.se 参考文章(59)
Filippo Pietrantonio, Vincenzo Mazzaferro, Rosalba Miceli, Christian Cotsoglou, Flavia Melotti, Giuseppe Fanetti, Federica Perrone, Pamela Biondani, Cecilia Muscarà, Maria Di Bartolomeo, Jorgelina Coppa, Claudia Maggi, Massimo Milione, Elena Tamborini, Filippo de Braud, Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases Medical Oncology. ,vol. 32, pp. 182- ,(2015) , 10.1007/S12032-015-0638-3
Liang Li, Hongyang Wang, Heterogeneity of liver cancer and personalized therapy Cancer Letters. ,vol. 379, pp. 191- 197 ,(2016) , 10.1016/J.CANLET.2015.07.018
Hongliang Du, Mengrui Liu, Xiaoye Yang, Guangxi Zhai, The role of glycyrrhetinic acid modification on preparation and evaluation of quercetin-loaded chitosan-based self-aggregates. joint international conference on information sciences. ,vol. 460, pp. 87- 96 ,(2015) , 10.1016/J.JCIS.2015.08.049
Wing-Hin Lee, Ching-Yee Loo, Daniela Traini, Paul M. Young, Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges Asian Journal of Pharmaceutical Sciences. ,vol. 10, pp. 481- 489 ,(2015) , 10.1016/J.AJPS.2015.08.009
Roonak Saadati, Simin Dadashzadeh, Zahra Abbasian, Abdolhamid Parsa, Saeed Azad Aramaki, Enhanced Permeability of Etoposide across Everted Sacs of Rat Small Intestine by Vitamin E-TPGS. Iranian Journal of Pharmaceutical Research. ,vol. 12, pp. 37- 46 ,(2013) , 10.22037/IJPR.2013.1270
Cuixia Yang, Linyan He, Pingqing He, Yiwen Liu, Wenjuan Wang, Yiqing He, Yan Du, Feng Gao, Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway Medical Oncology. ,vol. 32, pp. 1- 8 ,(2015) , 10.1007/S12032-014-0352-6
Rajaletchumy Veloo Kutty, Si-Shen Feng, Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials. ,vol. 34, pp. 10160- 10171 ,(2013) , 10.1016/J.BIOMATERIALS.2013.09.043
Dennis W. Lynch, William J. Moorman, Jeann R. Burg, Frederick C. Phipps, Trent R. Lewis, Amir Khan, Daniel M. Lewis, Francis W. Chandler, Renate D. Kimbrough, Thomas J. Spira, Subchronic inhalation toxicity of isobutyl nitrite in BALB/c mice. I. Systemic toxicity. Journal of Toxicology and Environmental Health. ,vol. 15, pp. 823- 833 ,(1985) , 10.1080/15287398509530708
Zhi Yao He, Xi Zheng, Xiao Hua Wu, Xiang Rong Song, Gu He, Wen Fang Wu, Shui Yu, Sheng Jun Mao, Yu Quan Wei, Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery International Journal of Pharmaceutics. ,vol. 397, pp. 147- 154 ,(2010) , 10.1016/J.IJPHARM.2010.06.029
Katel Marigny, Fabienne Aubin, Gwenola Burgot, Edouard Le Gall, Virginie Gandemer, Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible? Cancer Chemotherapy and Pharmacology. ,vol. 55, pp. 244- 250 ,(2005) , 10.1007/S00280-004-0858-2